Provention Bio, Inc. (NasdaqGS: PRVB)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Provention Bio, Inc. (NasdaqGS: PRVB) operates in the Pharmaceuticals industry within the Health Care sector.
Tweenvest scores Provention Bio, Inc. across four factors: quality 35/100, value 35/100. Its strongest factor is quality.
PRVB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $12.89M
- P/E
- —
- EPS
- -1.52
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 174
- Next earnings
- —
About Provention Bio, Inc.
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
- ISIN
- US74374N1028
- Founded
- 2016
- Listed since
- Jul 24, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Regnum Corp.OTCPK: RGMP | $23.00 | $— | — |
| CanaQuest Medical Corp.OTCPK: CANQ.F | $21.00 | $— | — |
| The Greenrose Holding Company Inc.OTCPK: GNRS.Q | $18.00 | $— | — |
| Lowell Farms Inc.OTCPK: LOWL.F | $18.00 | $0.00 | — |
| West Island Brands Inc.OTCPK: WIBF.F | $17.00 | $0.00 | — |
| 9 Meters Biopharma, Inc.OTCPK: NMTR.Q | $14.00 | $— | — |
| Biostar Pharmaceuticals, Inc.OTCPK: BSPM | $3.00 | $0.00 | — |
| BC Craft Supply Co. Ltd.OTCPK: CRFT.F | $2.00 | $— | — |
Figures last refreshed Oct 11, 2026.